• 1
    Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 76308.
  • 2
    Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2717681.
  • 3
    Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 1447782.
  • 4
    Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 3504652.
  • 5
    Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 1447784.
  • 6
    Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 218338.
  • 7
    Schatteman K, Goossens F, Scharpe S, Hendriks D. Proteolytic activation of purified human procarboxypeptidase U. Clinica Chimica Acta 2000; 292: 2540.
  • 8
    Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin–thrombomodulin complex. J Biol Chem 1996; 271: 166038.
  • 9
    Campbell W, Yonezu K, Shinohara T, Okada H. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J Lab Clin Med 1990; 115: 6102.
  • 10
    Hendriks D, Wang W, Scharpe S, Lommaert MP, Van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 8692.
  • 11
    Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 124105.
  • 12
    Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 1286878.
  • 13
    Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 102130.
  • 14
    Leurs J, Wissing BM, Nerme V, Schatteman K, Björquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 26471.
  • 15
    Stromqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T, Scharpé S, Hendriks D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 127.
  • 16
    Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res 1997; 85: 13345.
  • 17
    Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 1593744.
  • 18
    Hendriks D, Scharpe S, Van Sande M. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid. Clin Chem 1985; 31: 19369.
  • 19
    Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 80713.
  • 20
    Wu C, Dong N, Da Cunha V, Martin-McNulty B, Tran K, Nagashima M, Wu Q, Morser J, Wang YX. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90: 41421.
  • 21
    Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998; 79: 3717.
  • 22
    Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 511.
  • 23
    Deinum J, Elg S. The effect of melagatran on the binding of thrombin to antithrombin studied by plasmon resonance. Thromb Haemost 2000; 30 (Suppl. 1): 165.
  • 24
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 6616.